DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
Balance Sheet
Inspect the capital base behind the business.
Assets
$61.37M
FY 2025 · Annual
+32.4% YoYLiabilities
$5.26M
FY 2025 · Annual
-6.5% YoYEquity
$56.11M
FY 2025 · Annual
+37.8% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $4.9M |
| Short-term Investments | $46.5M |
| Other Current | $1.0M |
| Total Current Assets | $52.4M |
| PP&E (Net) | $317.0K |
| Other Non-current | $400.0K |
| Total Non-current Assets | $717.0K |
| Total Assets | $53.1M |
Analysis
Selected assets total $53.1M for Latest. The largest visible component is Short-term Investments at $46.5M, about 87.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 12, 2026 | |
| S-8 | S-8 filing | Aug 11, 2026 | |
| 10-Q | Quarterly report | Aug 10, 2026 |
How much cash does DMAC have?
DiaMedica Therapeutics Inc. (DMAC) reported $15.65M in cash and equivalents in fiscal 2025.
How much debt does DMAC carry?
DiaMedica Therapeutics Inc. (DMAC) reported $240,000.00 of total debt, with net debt of -$15.41M.
Continue the stock analysis
Jump to another research area for this company.